<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01083394</url>
  </required_header>
  <id_info>
    <org_study_id>GE IDE No. B00210</org_study_id>
    <nct_id>NCT01083394</nct_id>
  </id_info>
  <brief_title>Paclitaxel Eluting Balloon and Conventional Balloon for In-Stent Restenosis of the Superficial Femoral Artery</brief_title>
  <acronym>ISAR-PEBIS</acronym>
  <official_title>Randomized Trial of Paclitaxel Eluting Balloon or Conventional Balloon for Treatment of In-Stent Restenosis of the Superficial Femoral Artery in Patients With Symptomatic Peripheral Artery Disease (ISAR-PEBIS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Deutsches Herzzentrum Muenchen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to perform a randomized, controlled trial to compare percutaneous
      transluminal angioplasty using paclitaxel eluting balloon (PEB) or using a conventional
      balloon for treatment of superficial femoral artery in-stent restenosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The superficial femoral artery is a common place for arteriosclerosis in patients symptomatic
      for lower extremity vascular disease. Advances in percutaneous transluminal angioplasty (PTA)
      and stenting have provided new options for the treatment of the disease in this arterial
      segment. Restenosis after PTA occurs in 40-60% within one year. A novel attempt to reduce
      restenosis is the use of paclitaxel eluting balloons (PEB). First clinical studies suggest
      that the use of PEBs during percutaneous treatment of femoropopliteal disease is associated
      with significant reductions in late lumen loss and target-lesion revascularization. There is
      no randomized comparison of these treatments in patients with in stent restenosis of the
      superficial femoral artery. Thus, the aim of this study was to compare the efficacy of PTA
      with conventional balloon or PEB for in stent restenosis in the SFA in terms of reduction of
      diameter stenosis at follow-up angiogram.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2010</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage diameter stenosis</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse peripheral events (MAPE) defined as acute thrombosis of SFA or ipsilateral amputation or revascularization (PTA or bypass surgery)</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of any of MAPE</measure>
    <time_frame>3-24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binary restenosis rate</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage diameter stenosis in duplex ultrasound</measure>
    <time_frame>6 and 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Peripheral Vascular Disease</condition>
  <arm_group>
    <arm_group_label>conventional PTA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In stent restenosis is treated with PTA using a conventional balloon.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PTA with PEB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In stent restenosis is treated with PTA using a paclitaxel eluting balloon.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PTA</intervention_name>
    <description>PTA using a conventional balloon</description>
    <arm_group_label>conventional PTA</arm_group_label>
    <other_name>PACIFIC XTREME, Invatec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PTA with PEB</intervention_name>
    <description>PTA using a paclitaxel eluting balloon</description>
    <arm_group_label>PTA with PEB</arm_group_label>
    <other_name>IN.PACT PACIFIC, Invatec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous Transluminal Angioplasty (PTA)</intervention_name>
    <description>Percutaneous transluminal angioplasty with conventional balloon or paclitaxel-eluting balloon</description>
    <arm_group_label>conventional PTA</arm_group_label>
    <arm_group_label>PTA with PEB</arm_group_label>
    <other_name>PACIFIC XTREME or IN.PACT PACIFIC balloons</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic â‰¥ 70% in-stent restenosis of the AFS, (Rutherford stage 2-6)

          -  Written, informed consent by the patient or her/his legally-authorized representative
             for participation in the study

        Exclusion Criteria:

          -  Acute ischemia and/or acute thrombosis of the SFA

          -  Untreated ipsilateral iliac artery stenosis &gt;70%

          -  Not at least one vessel run-off

          -  Popliteal involvement with stenosis &gt;70%

          -  Severe renal insufficiency (GFR &lt;30 ml/min/m2)

          -  Malignancies or other comorbid conditions (for example severe liver, renal and
             pancreatic disease) with life expectancy less than 12 months or that may result in
             protocol non-compliance.

          -  Pregnancy (present, suspected or planned) or positive pregnancy test.

          -  Previous enrollment in this trial.

          -  Patient's inability to fully cooperate with the study protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adnan Kastrati, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ilka V. Ott, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum rechts der Isar</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julinda Mehilli, MD</last_name>
    <phone>+49 89 12 18</phone>
    <phone_ext>4582</phone_ext>
    <email>mehilli@dhm.mhn.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ilka V. Ott, MD</last_name>
    <phone>+49 89 41 40</phone>
    <phone_ext>4360</phone_ext>
    <email>ott@dhm.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>1. Medizinische Klinik, Klinikum rechts der Isar</name>
      <address>
        <city>Muenchen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilka V. Ott, MD</last_name>
      <phone>+49 89 4140</phone>
      <phone_ext>4360</phone_ext>
      <email>ott@dhm.mhn.de</email>
    </contact>
    <investigator>
      <last_name>Ilka V. Ott, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum</name>
      <address>
        <city>Muenchen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Massimiliano Fusaro, MD</last_name>
      <phone>+49 89 1218</phone>
      <phone_ext>4566</phone_ext>
      <email>fusaro@dhm.mhn.de</email>
    </contact>
    <contact_backup>
      <last_name>Tarek Ibrahim, MD</last_name>
      <phone>+49 89 1218</phone>
      <phone_ext>4016</phone_ext>
      <email>ibrahim@dhm.mhn.de</email>
    </contact_backup>
    <investigator>
      <last_name>Massimiliano Fusaro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2010</study_first_submitted>
  <study_first_submitted_qc>March 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2010</study_first_posted>
  <last_update_submitted>March 7, 2014</last_update_submitted>
  <last_update_submitted_qc>March 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PTA</keyword>
  <keyword>paclitaxel</keyword>
  <keyword>restenosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

